Table 3.
Estimation of non-adherence costs in our sample of schizophrenia patients (N = 17). Example of two patients from the “Enriched Environment withTechnology” (EET) group.
| Patient # | Medication | AAR (%) | Price per unit ($/u) | Unused costs per year (CAD) |
|---|---|---|---|---|
| EET-01 (AAR = 96.08%) | COGENTIN 2 mg | 93.33 | 0.23 | $ 35.62 |
| SEROQUEL XR 400 mg | 100 | 4.56 | ||
| ZELDOX 40 mg | 94.74 | 1.94 | ||
| ZELDOX 60 mg | 92.31 | 1.94 | ||
| SEROQUEL XR 200 mg | 100 | 2.46 | ||
| EET-20 (AAR = 42%) | PMS-PROCYCLIDINE 2.5 mg | 42.86 | 0.24 | $ 1,638.43 |
| HALOPERIDOL 2 mg | 42.86 | 0.12 | ||
| HALOPERIDOL 5 mg | 42.86 | 0.18 | ||
| GLUCOPHAGE 500 mg | 40.82 | 0.39 | ||
| VENLAFAXINE XR 150 mg | 38.78 | 2.24 | ||
| GEN-CLOZAPINE 50 mg | 42.86 | 0.7 | ||
| GEN-CLOZAPINE 200 mg | 42.86 | 1.9 | ||
| Total (N = 17) | 63.51 | $ 9,823.83 |
AAR, antipsychotic adherence ratio.